Charles River Laboratories International Inc's market capitalization of $11,581,570,153 is ahead of 85.75% of US-listed equities.
CRL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 316.82 -- higher than 89.07% of US-listed equities with positive expected earnings growth.
The price/operating cash flow metric for Charles River Laboratories International Inc is higher than 78.65% of stocks in our set with a positive cash flow.
If you're looking for stocks that are quantitatively similar to Charles River Laboratories International Inc, a group of peers worth examining would be RXN, BFAM, TTEK, ICLR, and CLGX.
CRL's SEC filings can be seen here. And to visit Charles River Laboratories International Inc's official web site, go to www.criver.com.
Charles River Laboratories International, Inc. (CRL) Company Bio
Charles River Laboratories provides products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. The company was founded in 1947 and is based in Wilmington, Massachusetts.
CRL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Charles River Laboratories International Inc. To summarize, we found that Charles River Laboratories International Inc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Charles River Laboratories International Inc ended up being:
Charles River Laboratories International Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 5.92. This coverage rate is greater than that of 66.36% of stocks we're observing for the purpose of forecasting via discounted cash flows.
The weighted average cost of capital for the company is 8. This value is greater than merely 19.54% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CRL, try GSK, PRGO, ENDP, HZNP, and MD.
Comet Resources Ltd (Comet or the Company) (ASX:CRL) is pleased to announce that is has executed binding documents with Raptor Capital International Limited The post Streaming Agreement for up to US$20M Finalised appeared first on Investing News Network .
Charles River Laboratories' (CRL) stock has performed well so far in 2020, as CRL shares are outperforming the broader market by ~35 percentage points over the last 8 plus months. Data by YCharts And it helps the bull case that the company's Q2 2020 results were well-received by the market,...
WG Investment Research on Seeking Alpha | August 16, 2020
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Small-Cap Growth Fund posted a return of 34.59% for the quarter, outperforming its benchmark, the Russell 2000 Growth Index which returned 30.59% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for […]